Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;45(5):578-581.
doi: 10.1007/s00270-021-03012-y. Epub 2021 Dec 2.

Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt

Jenny Yan  1 , Xiaohan Ying  2 , Anuj Malhotra  3 , Adam Talenfeld  3 , Resmi Charalel  3 , Kyungmouk Steve Lee  3 , David Trost  3 , Andrew Kesselman  3
Affiliations

Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt

Jenny Yan et al. Cardiovasc Intervent Radiol. 2022 May.

Abstract

This retrospective analysis reviews five patients with transjugular intrahepatic portosystemic shunt (TIPS) who underwent percutaneous microwave ablation of hepatocellular carcinoma between January 2017 and September 2020. Mean tumor diameter was 2.0 cm (range 1.3-2.9 cm), and mean tumor distance from TIPS was 2.3 cm (range 1.5-3.3 cm). There were no major adverse events, and the TIPS patency was 100% post-ablation. The technical success rate was 100%, and the complete response rate was 100%. In this small study, percutaneous microwave ablation appears safe and effective for the treatment of hepatocellular carcinoma in patients with TIPS in the short-term follow-up period.

Keywords: Hepatocellular carcinoma (HCC); Microwave ablation (MWA); Transjugular intrahepatic portosystemic shunt (TIPS).

PubMed Disclaimer

References

    1. Yang JD, Hainaut P, Gores FJ, Amadou A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. - DOI
    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27. - DOI
    1. Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers. 2019;11(8):1085. - DOI
    1. Shiina S, Sato K, Tateishi R, et al. (2018). Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol. 4756147.
    1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50. - DOI

MeSH terms

LinkOut - more resources